Find trials
Consejos para buscar

A Registry of Antifungal Therapy in Adults with Either Invasive Mucormycosis or Invasive Aspergillosis

Overview

Información sobre este estudio

The objective is to obtain and report outcome data for adult subjects who received systemic antifungal therapy (AFT) for the treatment of invasive mucormycosis (IM) or invasive aspergillosis (IA) caused by a non-fumigatus species.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria

  • Proven or probable IM or IA caused by a non-fumigatus species per EORTC/MSG criteria
  • Multiple fungal pathogens are eligible (i.e., niger/fumigatus, Rhizopus/Absidia)
  • Age 18 years at time began treatment with a systemic AFT for their IFI
  • Has received or is receiving treatment with a systemic AFT active against IM or IA caused by a non-fumigatus species
  • Initiated systemic AFT for treatment of IM or IA caused by a non-fumigatus species in January 2016 or later
  • Subject or legal representative has provided the appropriate consent and/or release, consistent with local requirements, to access medical records if required by institutional policy, state and/or governmental laws, including access to all relevant clinical and medication data, and the storage and analysis of this data
  • Has completed therapy prior to registration must have day 42 vital status data available

Exclusion Criteria

  • Only underwent surgery for the treatment of IM or IA caused by a non-fumigatus species (i.e. did not receive systemic antifungal treatment)
  • Previously provided data for this registry
  • Received an investigational drug used to treat an IFI within 30 days of starting treatment with an approved antifungal for their IFI

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

Jason Barreto, Pharm.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available

Otros temas en investigación

.
CLS-20315996

Mayo Clinic Footer